Clinical Trial Update: QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating QL1706 in combination with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone for locally advanced, resectable esophageal s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING